Literature DB >> 25808231

Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis-TAFRO syndrome.

Preetesh Jain1, Srdan Verstovsek1, Sanam Loghavi2, Jeffrey L Jorgensen2, Keyur P Patel2, Zeev Estrov1, Luis Fayad3, Naveen Pemmaraju1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25808231      PMCID： PMC4580493          DOI： 10.1002/ajh.24015

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  5 in total

1.  [Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly].

Authors:  Kazue Takai; Koji Nikkuni; Hiroyuki Shibuya; Hideki Hashidate
Journal:  Rinsho Ketsueki       Date:  2010-05

2.  Castleman-Kojima disease (TAFRO syndrome) : a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly : a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012).

Authors:  Hiroshi Kawabata; Kazue Takai; Masaru Kojima; Naoya Nakamura; Sadao Aoki; Shigeo Nakamura; Tomohiro Kinoshita; Yasufumi Masaki
Journal:  J Clin Exp Hematop       Date:  2013

3.  Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study.

Authors:  Ayalew Tefferi; Rakhee Vaidya; Domenica Caramazza; Christy Finke; Terra Lasho; Animesh Pardanani
Journal:  J Clin Oncol       Date:  2011-02-07       Impact factor: 44.544

4.  Successful treatment of a patient with multicentric Castleman's disease who presented with thrombocytopenia, ascites, renal failure and myelofibrosis using tocilizumab, an anti-interleukin-6 receptor antibody.

Authors:  Hiroshi Kawabata; Shin-ichi Kotani; Yumi Matsumura; Tadakazu Kondo; Tatsuya Katsurada; Hironori Haga; Norimitsu Kadowaki; Akifumi Takaori-Kondo
Journal:  Intern Med       Date:  2013-07-01       Impact factor: 1.271

5.  Successful treatment of a Caucasian case of multifocal Castleman's disease with TAFRO syndrome with a pathophysiology targeted therapy - a case report.

Authors:  Silvia Tedesco; Laura Postacchini; Lucia Manfredi; Gaia Goteri; Michele M Luchetti; Antonella Festa; Armando Gabrielli; Giovanni Pomponio
Journal:  Exp Hematol Oncol       Date:  2015-01-14
  5 in total
  12 in total

1.  Aggressive TAFRO syndrome with reversible cardiomyopathy successfully treated with combination chemotherapy.

Authors:  Shunichiro Yasuda; Keisuke Tanaka; Ayako Ichikawa; Ken Watanabe; Emi Uchida; Masahide Yamamoto; Kouhei Yamamoto; Daisuke Mizuchi; Osamu Miura; Tetsuya Fukuda
Journal:  Int J Hematol       Date:  2016-05-31       Impact factor: 2.490

2.  TAFRO syndrome: A case report and review of the literature.

Authors:  Tieying Hou; Jaspreet Dhillon; Wenbin Xiao; Elaine S Jaffe; Amy M Sands; Vishala Neppalli; George Deeb; Nan Zhang
Journal:  Hum Pathol (N Y)       Date:  2017-04-21

Review 3.  Successful Treatment of TAFRO Syndrome with Tocilizumab, Prednisone, and Cyclophosphamide.

Authors:  Taku Kikuchi; Takayuki Shimizu; Takaaki Toyama; Ryohei Abe; Shinichiro Okamoto
Journal:  Intern Med       Date:  2017-08-01       Impact factor: 1.271

4.  Idiopathic multicentric Castleman's disease: a clinicopathologic study in comparison with IgG4-related disease.

Authors:  Kyoko Otani; Dai Inoue; Kohei Fujikura; Takahiro Komori; Shiho Abe-Suzuki; Takuma Tajiri; Tomoo Itoh; Yoh Zen
Journal:  Oncotarget       Date:  2018-01-09

5.  Two Cases of Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis/Renal Failure, and Organomegaly (TAFRO) Syndrome with High Serum Procalcitonin Levels, Including the First Case Complicated with Adrenal Hemorrhaging.

Authors:  Mizuho Nara; Atsushi Komatsuda; Fumiko Itoh; Hajime Kaga; Masaya Saitoh; Masaru Togashi; Yoshihiro Kameoka; Hideki Wakui; Naoto Takahashi
Journal:  Intern Med       Date:  2017-05-15       Impact factor: 1.271

6.  Remission of Refractory Ascites and Discontinuation of Hemodialysis after Additional Rituximab to Long-term Glucocorticoid Therapy in a Patient with TAFRO Syndrome.

Authors:  Hanako Tsurumi; Yoshihide Fujigaki; Tadashi Yamamoto; Risa Iino; Kei Taniguchi; Michito Nagura; Shigeyuki Arai; Yoshifuru Tamura; Tatsuru Ota; Shigeru Shibata; Fukuo Kondo; Nozomu Kurose; Yasufumi Masaki; Shunya Uchida
Journal:  Intern Med       Date:  2018-01-11       Impact factor: 1.271

7.  Clinical features and treatment of 7 Chinese TAFRO syndromes from 96 de novo Castleman diseases: a 10-year retrospective study.

Authors:  Yi Zhang; Shan-Shan Suo; Han-Jin Yang; Xin-Ping Zhou; Liang-Shun You; Wen-Juan Yu; Zhao-Ming Wang; Jie Jin
Journal:  J Cancer Res Clin Oncol       Date:  2020-01-14       Impact factor: 4.553

Review 8.  Clinicopathological features of progressive renal involvement in TAFRO syndrome: A case report and literature review.

Authors:  Mari Tanaka; Hiraku Tsujimoto; Kojiro Yamamoto; Saeko Shimoda; Kazumasa Oka; Hiroya Takeoka
Journal:  Medicine (Baltimore)       Date:  2017-10       Impact factor: 1.889

9.  Successful rituximab treatment of TAFRO syndrome with pathological findings of glomerular endothelial damage.

Authors:  Yuhei Noda; Yosuke Saka; Akihisa Kato; Tetsushi Mimura; Tomohiko Naruse
Journal:  Clin Nephrol Case Stud       Date:  2018-06-22

10.  Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis/Renal Failure, and Organomegaly (TAFRO) Syndrome with Bilateral Adrenal Hemorrhage in Two Caucasian Patients.

Authors:  Grégoire Ducoux; Arthur Guerber; Cécile-Audrey Durel; Bouchra Asli; Jehane Fadlallah; Arnaud Hot
Journal:  Am J Case Rep       Date:  2020-04-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.